AXT Inc vs TG Therapeutics Inc — how do they compare? AXT Inc trades at $78.92 (market cap $4.83B), while TG Therapeutics Inc trades at $49.65 (market cap $7.64B). The key difference: TG Therapeutics Inc is the larger of the two by market cap, and TG Therapeutics Inc is trading nearer its 52-week high, AXT Inc nearer its low. Which is the better fit depends on your goals.
| AXTI | TGTX | |
|---|---|---|
Market Cap | $4.83B | $7.64B |
Sector | Technology | Health |
52-Week High | $140.83 | $59.06 |
52-Week Low | $2.05 | $26.94 |
Enterprise Value | $4.50B | $7.84B |
Signals from Pluang's Aura AI — not financial advice
AXTI trades at $88.58, up 17.84% in 24 hours, reflecting strong momentum after Q2 2026 earnings beat. The stock is technically bullish with support at $82 and resistance at $92. Fundamentally, revenue grew to $126 million in 2026 with a net profit margin of 3.23%, though valuation ratios like P/E of 2,460.33 appear elevated. Recent news highlights surging indium phosphide demand driven by AI data centers.
Outlook is positive with analyst consensus at Buy (72.73%) and a $72.50 price target, but risks include high valuation, cash flow volatility, and dependence on AI-driven demand. The stock offers growth exposure to semiconductor substrates, yet investors should weigh profitability sustainability against rich multiples.
TG Therapeutics (TGTX) trades at $49.76, up 0.42% in the last session, with a bearish technical signal from moving averages. Recent earnings missed estimates, but revenue growth is strong, driven by BRIUMVI sales, with 2026 guidance raised to $950 million. The stock faces near-term pressure from earnings underperformance and a legal investigation into potential fiduciary breaches.
The outlook is mixed: strong revenue momentum and a high analyst buy rating (84.62%) support upside to the $63.75 consensus target, but risks include earnings volatility, high valuation multiples, and legal overhangs. Investors should weigh robust growth prospects against execution and sentiment challenges.
Trailing returns across standard periods
Latest headlines on both assets
AXT develops and manufactures high-performance compound semiconductor wafer substrates. Its products, like indium phosphide and gallium arsenide, are essential for data centers, 5G, and consumer electronics.
Read more on AXTI →TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →